Hepatitis D Virus Market Outlook Report 2030

1. Hepatitis D Virus Market Outlook Report 2030 DelveInsight’s‘Hepatitis D Virus (HDV) Market Report 2030’ delivers an in-depth understanding of the HDV, historical and forecasted epidemiology as well as the HDV market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. Geographies Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan Study Period: 2017–2030 Request for sample pages: https://www.delveinsight.com/sample- request/hepatitis-d-market Hepatitis D Virus Disease Overview Hepatitis D is caused by infection with the hepatitis D virus, also known as Delta Virus, and is considered to be the most severe form of viral hepatitis in humans due to more rapid progression toward liver-related death and hepatocellular carcinoma. HDV occurs only in individuals positive for the hepatitis B virus (HBV) surface antigen (HBsAg) as HDV is a defective RNA viroid that requires HBsAg for transmission. HDV shares common modes of transmission as HBV and can be acquired either as coinfection or superinfection to HBV. Simultaneous infection (i.e. co-infection) with HBV and HDV can lead to a mild-to-severe or even fulminant hepatitis, whereas the super-infection of HDV on chronic hepatitis B accelerates progression to a more severe disease in all ages and in 70‒90% of people. The mode of transmission is commonly through contact with blood or other body fluids, including sexual contact with an infected partner, injection-drug use that involves sharing needles, syringes, or drug-preparation equipment and needle sticks or exposures to sharp instruments. Vertical transmission from mother to child is rare. Infection with Hepatitis D Virus can worsen symptoms of HBV infection or hepatitis B-associated liver disease. Hepatitis D Virus Symptoms

2.       Yellowing of the skin and eyes (jaundice) Gastrointestinal (GI) issues such as nausea, vomiting, and abdominal pain Tiredness Loss of appetite Dark-colored urine Joint pain Hepatitis D Virus Treatment Hepatitis D Virus treatment options are limited and optimal treatment is not known. There are no known treatments for acute HDV. The goal of treatment is to suppress HDV replication which is shown by the inability to detect HDV RNA in serum and HDAg in the liver. Pegylated interferon-alpha has shown some efficacy, but the sustained virologic response rate (a measure of viral clearance) is low. The pegylated form of IFN alpha is recommended to be the preferred agent as per expert guidelines. Hepcludex is the first therapy approved in Europe and has been granted Conditional Marketing Authorization (CMA) for the treatment of HDV. It works as an entry inhibitor that is, it prevents HDV cells and the HBV cells upon which HDV is prevented, from entering healthy liver cells. Liver transplantation is the only treatment option for patients with end-stage liver cirrhosis resulting from HDV. Hepatitis D Virus Epidemiology Insights The Hepatitis D Virus epidemiology division provides insights about the historical and current HDV patient pool and forecasted trends for every seven major countries. Key Findings 1. In the year 2017, the Total Diagnosed Prevalent cases of Hepatitis D Virus was 204,976 in the 7MM which are expected to grow during the study period, i.e., 2017–2030. 2. Estimates show that the highest cases of Hepatitis D Virus in the 7MM were in the United States, followed by Japan, Germany, Italy, Spain, the United Kingdom, and France in 2017. Country Specific Epidemiology Insights:  In the United States, the total diagnosed prevalent cases of HDV was 112,673 cases in the year 2017 which are expected to grow during the study period, i.e., 2017–2030. In the year 2017, the total diagnosed prevalent cases of HDV were 64,845 cases in EU-5 which are expected to grow during the study period, i.e., 2017–2030. In Japan, the total diagnosed prevalent cases of HDV was 27,458 cases in the year 2017 which are expected to grow during the study period, i.e., 2017–2030. Hepatitis D Virus Drug Emerging Therapy Assessment  Hepcludex/Bulevirtide (MYR Pharmaceuticals/Hepatera)  Lonafarnib (Eiger Biopharmaceuticals)  Peginterferon Lambda (Eiger Biopharmaceuticals)  

3.  JNJ-73763989 (Janssen Biopharmaceuticals) Hepatitis D Virus Market Outlook Currently, treatment strategies for HDV mainly include interferon (IFN)-based therapy. Antiviral therapy with interferon alfa can be considered in patients with chronic hepatitis D virus (HDV) infection. The treatment course is usually at least 1 year. PegIFNa is the only available drug that has been proven to have some antiviral efficacy against chronic HDV infection. Interferons may be effective at a very early stage of infection when HDV is entering hepatocytes rather than at the stage of established intracellular hepatocyte HDV infection. Recently, Hepcludex has been approved as the first treatment option for adult patients with chronic HDV infection and compensated liver disease in Europe. At present, some companies have indulged themselves to initiate clinical trials that investigate new treatment options. Key players such as Eiger Biopharmaceuticals (Lonafarnib, Peginterferon Lambda- 1A), Janssen Pharmaceuticals (JNJ-73763989), and several others are investigating their candidates for the management of HDV in the 7MM. The Hepatitis D Virus market size in the 7MM is expected to change during the study period 2017– 2030. The therapeutic market of HDV in the seven major markets was USD 285.1 million in 2017 which is expected to increase during the study period (2017–2030). According to the estimates, the highest market size of HDV is found in the United States followed by Japan and Germany. Download Hepatitis D Virus https://www.delveinsight.com/report-store/hepatitis-d-market Market Report @